Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies

Lebrikizumab rapidly improved skin and itch symptoms in four weeks INDIANAPOLIS , March 26, 2022 /PRNewswire/ -- More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity ( EASI -75 * ) at 16 weeks when receiving